Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Method for determination of sensitivity to anti-cancer agent
US9089540B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9089540-B2 |
| Application number | US-86572609-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 30, 2009 |
| Priority date | Jan 31, 2008 |
| Publication date | Jul 28, 2015 |
| Grant date | Jul 28, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are an marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a calcium-binding protein S100A7, S100A8, or S100A10.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating colorectal cancer, comprising: (1) measuring a concentration of at least one calcium-binding protein selected from the group consisting of S100A7, S100A8, and S100A10 in a biological specimen from a subject with colorectal cancer; and (2) administering at least one anticancer agent selected from the group consisting of oxaliplatin, cisplatin, irinotecan, SN-38, and a salt thereof to the subject when the concentration of the calcium-binding protein is lower than a predetermined standard concentration for the anticancer agent, or when the concentration of the calcium binding protein does not reach a predetermined standard concentration which is set for the anticancer agent during the administration of the anticancer agent, excluding the combination of S100A10 and cisplatin. 2. The method of claim 1 , which comprises (2) administering at least one anticancer agent selected from the group consisting of oxaliplatin, cisplatin, irinotecan, SN-38, and a salt thereof to the subject when the concentration of the calcium-binding protein is lower than a predetermined standard concentration for the anticancer agent. 3. The method of claim 1 , wherein the calcium-binding protein is S100A7. 4. The method of claim 1 , wherein the calcium-binding protein is S100A8. 5. The method of claim 1 , wherein the calcium-binding protein is S100A10. 6. The method of claim 1 , wherein the anticancer agent is oxaliplatin or a salt thereof. 7. The method of claim 1 , wherein the anticancer agent is cisplatin or a salt thereof. 8. The method of claim 1 , wherein the anticancer agent is irinotecan or a salt thereof. 9. The method of claim 1 , wherein the anticancer agent is SN-38 or a salt thereof. 10. The method of claim 1 , wherein the subject has received the anticancer agent. 11. The method of claim 1 , wherein the biological specimen is blood, plasma, a biopsy specimen of a cancer tissue, a preparation obtained by cancer extirpation, stool, urine, ascitic fluid, pleural fluid, cerebrospinal fluid, or expectoration. 12. The method of claim 1 , wherein the biological specimen is serum. 13. The method of claim 1 , wherein the concentration of the calcium-binding protein is measured by mass spectrometry. 14. The method of claim 1 , wherein the concentration of the calcium-binding protein is measured with an antibody to the marker. 15. The method of claim 1 , wherein the concentration of the calcium-binding protein is measured by radioimmunoassay, an enzyme immunoassay, a fluorescent immunoassay, a luminescence immunoassay, immunoprecipitation, immunonephelometry, immunostaining, or immunodiffusion. 16. The method of claim 1 , wherein the concentration of the calcium-binding protein is measured by western blotting. 17. The method of claim 1 , wherein the concentration of the calcium-binding protein is measured by enzyme-linked immunosorbent assay.
Assignees
Inventors
Classifications
- A61K31/282Primary
Platinum compounds · CPC title
Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9089540B2 cover?
- Provided are an marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a calcium-binding protein S100A7, S100A8, or S100A10.
- Who is the assignee on this patent?
- Tanigawara Yusuke, Suzuki Sayo, Sugimoto Shinji, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/282. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).